Closed Antares Pharma Acquisition, Accelerating High Growth Drug Delivery Leadership and Projected to be Accretive to Revenue for Full Year 2022
Second Quarter Revenue Increased 12% YOY to $152.4 million, with GAAP Diluted Earnings per Share of $0.16 and Non-GAAP Diluted Earnings per Share of $0.53
Record Second Quarter Royalty Revenue Increased 86% YOY to $85.3 million
Raising 2022 Revenue Guidance to $655 Million to $685 Million, up from $530 Million to $560 Million, Representing 48%-55% Growth over Reported 2021 Revenue
https://finance.yahoo.com/news/halozyme-reports-second-quarter-2022-200100443.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.